Skip to main content
Vincent Picozzi, MD, Oncology, Seattle, WA, Virginia Mason Medical Center

VincentJPicozziMD

Oncology Seattle, WA

Clinical Professor of Medicine, University Wash

Dr. Picozzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Picozzi's full profile

Already have an account?

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1981 - 1982
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1978

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1981 - Present
  • WA State Medical License
    WA State Medical License 1985 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
  • Super Doctor SuperDoctors.com
  • Top MD Consumers Checkbook

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative  
    Sameh Mikhail, Vincent J Picozzi, Clinical Cancer Research

Lectures

  • Prognostic value (PV) of pathologic response (PR) to neoadjuvant chemotherapy (NC) alone in resected pancreatic cancer (PDAC): Initial analysis. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
  • PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC). 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
  • Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 cl... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Virginia Mason Helps Lead National Clinical Trial to Accelerate Exploration, Approval of New Pancreatic Cancer Therapies
    Virginia Mason Helps Lead National Clinical Trial to Accelerate Exploration, Approval of New Pancreatic Cancer TherapiesMay 7th, 2020
  • Pancreatic Cancer Advocates Rally for More Federal Research Funding
    Pancreatic Cancer Advocates Rally for More Federal Research FundingJune 24th, 2019
  • Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data on Friday, January 18th
    Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data on Friday, January 18thJanuary 15th, 2019
  • Join now to see all

Hospital Affiliations